Active substance
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| QUVIVIQ | EQ 25MG BASE; EQ 50MG BASE | tablet · oral | IDORSIA | Prescription | 7 Jan 2022 |
Quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| QUVIVIQ | 02537443 | 50 MG | TABLET · ORAL | IDORSIA PHARMACEUTICALS LTD |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | QUVIVIQ 25 MG TABLET | $16.70464 | per EA | 23 Sep 2026 |
| US NADAC | QUVIVIQ 50 MG TABLET | $16.70464 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Daridorexant 25mg tablets | £42.00 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Daridorexant 50mg tablets | £42.00 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.